Share Name Share Symbol Market Type Share ISIN Share Description
Benchmark Holdings LSE:BMK London Ordinary Share GB00BGHPT808 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 51.00p 49.00p 53.00p - - - 0 06:30:43
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 109.4 -22.4 -4.4 - 266.41

Benchmark Holdings (BMK) Latest News

More Benchmark Holdings News
Benchmark Holdings Takeover Rumours

Benchmark Holdings (BMK) Share Charts

1 Year Benchmark Holdings Chart

1 Year Benchmark Holdings Chart

1 Month Benchmark Holdings Chart

1 Month Benchmark Holdings Chart

Intraday Benchmark Holdings Chart

Intraday Benchmark Holdings Chart

Benchmark Holdings (BMK) Discussions and Chat

Benchmark Holdings Forums and Chat

Date Time Title Posts
08/8/201711:32SALMON prices 30 year high and CAT VACCINES are Go-Go96
27/1/201714:29Benchmark Holdings Plc389

Add a New Thread

Benchmark Holdings (BMK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Benchmark Holdings trades in real-time

Benchmark Holdings (BMK) Top Chat Posts

Benchmark Holdings Daily Update: Benchmark Holdings is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker BMK. The last closing price for Benchmark Holdings was 51p.
Benchmark Holdings has a 4 week average price of 49.50p and a 12 week average price of 49.50p.
The 1 year high share price is 109.50p while the 1 year low share price is currently 49.50p.
There are currently 522,365,034 shares in issue and the average daily traded volume is 151,969 shares. The market capitalisation of Benchmark Holdings is £266,406,167.34.
simon gordon: What's fair value? Numis forecast it to do c.£11m PBT to 9/19. Market cap now £269m. Probably got some debt now, not sure how much. Give them 15x 11m = £165m market cap. So share price down into the 30's is feasible unless they start meeting their numbers and upgrading forecasts. They might want to consolidate the share so it doesn't look like a penny dribbler.
multibagger: Aha Janeann - we meet again ! I thought our investing styles were similar so I guess our paths cross frequently and I am pleased that we are doing well (atleast for now in a bull market). BMK is another of my decent sized holds - I think that the company has developed a great IP portfolio with multiple revenue streams, in different countries, across a range of sectors and this de-risks the company massively IMHO. I think that there is a real possibility of a takeover in due course given the barriers to entry by one of the agri giants. It was a steal when I started buying in the late 50s price range. I am confident that we will see a multipound share price over the next 3-5 years. Good luck :) Good decision re BOO - our values and principles are more important than a few pieces of silver !
multibagger: Thanks for the info Miss Womble - that could well explain the share price rise and agree that there could be more to come in the short term... hxxps:// Good luck all :)
multibagger: It would be interesting to see how the market reacts as the headline is about increasing equity and diluting EPS in the short term. The good thing is that the placement is at a decent premium to current share price. I agree that this is a very shrewd move in terms of increasing IP, getting into new areas and scalability, but won't be surprised if the share price is marked down a few pennies. Personally, I am not too bothered, as my investment horizon is about 3-5 years - I am confident that BMK will be taken out in due course at a good premium. Till that happens, the increasing share price and possible dividends will be most welcome !
pugugly: simon gordon:> imo Think of a figure and then halve it. Heavily loss making and integration of new merger not yet proven. Share price in free fall and probably big overhang from vendors - Do you have any knowledge of whether there is a "lock-in" period ? Also salmon in Chile I hear are suffering from disease (source from memory Bloomberg) PLUS of course my concerns (expressed above) as to whether this had been boosted too much by th e"Woodford effect" and is now suffering withdrawal symptoms. Very much on the side for the moment until profitability considered (by me) as likely in the foreseeable future.
briangeeee: The downgrade is massive, and worst of all it's in comparison with figures issued only a few months ago to support a huge acquisition and fund raise. At that point the Salmosan business was said to be going surprisingly well. In my opinion this huge downgrade totally destroys management's credibility, and I'm amazed Woodford has supported the share price. Perhaps he's trying to protect his large holding, and sees value in the pipeline. However, given that not only has the Salmosan been extremely disappointing, but it's replacement now being delayed by 15 months is another huge black mark. I don't see how anything they say can be believed. Obviously the new fish breeding business may be a success, but is it enough?
exbroker: This is the front page of a note from the broker Cenkos. Industry Transformative Deal Announced Benchmark is undertaking two highly transformative acquisitions that will, when blended together, create the foundations of a global business at the forefront of salmon genetics and primary breeding. We believe the opportunity for Benchmark to become a world class player across several animal health segments is readily achievable led by a highly capable management team. Our valuation of the enlarged company suggests a share price of 140p based on 2016 industry EBITDA multiples (including Zoetis) applied to our forecasts. We have therefore set our price target at this level. BUY.  Forecasts The year ended 30 September 2014 has been a year of strong delivery led by robust sales of Salmosan. We are upgrading our revenue forecasts for the base (pre-acquisition) business from £42.2m to £44.4m in 2015E and present revised forecasts for the new group (post acquisition) driving trading EBITDA from £11.8m to £21.9m in 2016.  Consolidation in salmon genetics Combining Stofnfiskur (FY14F T/O: £6.6m based Iceland) and SalmoBreed (FY14F T/O £9.8m Norway) will produce a global number 2 player. The key here is not strengths of the individual companies, but the strong synergies created by combining them. Marrying multi-decade development of male genetics with multi-decade development of salmon eggs, and leveraging the combined qualities on land-based bio-secure salmon farming to produce very high quality salmon ALL year round, is a unique global proposition. With salmon consumption growing at 7% per annum and supply barely achieving 3% - there is an opportunity to grow both pricing and volume dynamically in the near-term.  HypoPet opportunity compelling We have created a model to reflect the potential for the HypoPet cat vaccine and see £15m peak sales in the UK valuing the business at £55m (which is not included in our valuation as it is outside the forecast period). The potential sales for the product could significantly exceed the forecasts in our model with international sales likely to be in multiples of those achieved in the UK.  Pipeline progression and Outlook Benchmark has an industry leading pipeline (47 small molecules and vaccines – compared to 30 a year ago with the addition of the Zoetis vaccines business); a sector leading sustainability business and strong foundations in science (publishing) – coupled to salmon egg production using leading genetics, we see a strong future for the business.
thorne3: For the time being the share price is clearly being managed at 85p on the offer side.A number of institutions who bought in at the original placement price of 64p are gradually taking a modicum of profit;nothing wrong there.In due course this selling will be absorbed as the potentially exciting newsflow unfolds.At that stage the share price could move quite materially as the market as a whole begins to appreciate the attractions and very considerable potential of this amazing company.
simon gordon: dasv, Just caught your latest post, I suppose share price appreciation rests on how that pipeline develops and whether the vaccines business scales up quickly. They have scope for bolt-ons. It could be like a BTG where it goes sideways for a while then hits a strong growth curve and the share takes off and multi bags. BTG has six bagged since 2007. BMK does look a long term growth story, the quality is apparent, the global opportunities are large, the barriers to entry considerable. I think if it weakens down to the 80s it is a decent buy and multi year buy & forget.
hydrus: Be interesting to see what broker note says still. This could be a good long term bet but it is difficult to see what could take the share price higher in next few months let alone the very short term. Looking forward to hearing from the company also.
Benchmark Holdings share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20170821 06:50:53